Document Classification

Section Type: METHODS

Text: Patients with curatively resected stage III or high-risk stage II colon carcinoma were randomly assigned (1:1:1) to receive FOLFOX4 (oxaliplatin 85 mg/m (2), leucovorin 200 mg/m (2), and fluorouracil 400 mg/m (2) bolus plus 600 mg/m (2) 22-h continuous infusion on day 1 ; leucovorin 200 mg/m (2) plus fluorouracil 400 mg/m (2) bolus plus 600 mg/m (2) 22-h continuous infusion on day 2) every 2 weeks for 12 cycles ; bevacizumab 5 mg/kg plus FOLFOX4 (every 2 weeks for 12 cycles) followed by bevacizumab monotherapy 75 mg/kg every 3 weeks (eight cycles over 24 weeks) ; or bevacizumab 75 mg/kg plus XELOX (oxaliplatin 130 mg/m (2) on day 1 every 2 weeks plus oral capecitabine 1000 mg/m (2) twice daily on days 1-15) every 3 weeks for eight cycles followed by bevacizumab monotherapy 75 mg/kg every 3 weeks (eight cycles over 24 weeks).